



2018/12/10

Company:	CYBERDYNE, INC.
Name of Representative:	Yoshiyuki Sankai, President and CEO
Code:	7779 (Mothers Section of the Tokyo Stock Exchange)
Contact:	Shinji Uga, Director and CFO (Tel. +81-29-869-9981)

**Electrocardiogram and pulse wave measurement device that captures levels of arteriosclerosis was approved as a medical device by MHLW**

**~ Realizing prevention/examination of cardiovascular diseases such as stroke and heart attack ~**

CYBERDYNE, INC. (the “Company”) has received an approval for manufacturing and selling VS-AS01 Device for Electrocardiogram and Pulse Examination (the “Device”) as a medical device by the Ministry of Health Labour and Welfare. The palm-size device can easily measure arterial stiffness.

#### 1. About the Device

As part of its endeavor to prevent and examine cardiovascular diseases such as stroke and cardiac infarction, the Company developed this new Cybernic Device to detect early signs of arteriosclerosis and arrhythmia, which are major causes of those diseases. The application for medical device approval of this device was submitted in June 2018.

Measuring electrocardiograms and pulse waves, the device uses Pulse Wave Velocity (PWV) to examine arterial stiffness. Through the utilization of Cybernic Technology, the Company succeeded in making the Device the size of a palm, so as to easily be carried around and used for examination. Running an examination with the Device is very easy and can be completed in 30 seconds. The user first places a probe on their toe, then puts the Device on their abdominal region, and then presses the start button. Like other products of the Company, the Device is installed with Internet of Humans/Internet of Things function, enabling accumulation of the measured data.

“Japan Atherosclerosis Society Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases” stresses the necessity of recognizing the existence and extent of arteriosclerosis and controlling/treating related risk factors. The Device would help its users maintain their healthy state with its ability to simplify measurement methods and manage health data.

Following the approval, the Company will go through the process to obtain public health insurance coverage for the Device at the earliest convenience to accelerate its commercialization.

The Device would be offered in addition to the various other Cybernic Devices and Cybernic Interfaces that connect information from the human body to Super Computers. By analyzing the accumulated information/Big Data, the Company aims to prevent, examine and treat diseases with more personalized treatment programs and health management systems.

#### 2. Schedule

Impact towards the consolidated financial results for fiscal year ending March 31, 2019 is minimal, however if there is any related matter that should be disclosed, the Company will disclose it promptly